Phio Pharmaceuticals Corp (NASDAQ:PHIO) — Market Cap & Net Worth
Market Cap & Net Worth: Phio Pharmaceuticals Corp (PHIO)
Phio Pharmaceuticals Corp (NASDAQ:PHIO) has a market capitalization of $12.55 Million ($12.55 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26475 globally and #5463 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Phio Pharmaceuticals Corp's stock price $1.08 by its total outstanding shares 11617250 (11.62 Million). Review PHIO current and long-term liabilities to assess the company's total debt and financial obligations.
Phio Pharmaceuticals Corp Market Cap History: 2015 to 2026
Phio Pharmaceuticals Corp's market capitalization history from 2015 to 2026. Data shows change from $2.64 Trillion to $12.55 Million (-68.73% CAGR).
Index Memberships
Phio Pharmaceuticals Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #760 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2468 of 3165 |
Weight: Phio Pharmaceuticals Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Phio Pharmaceuticals Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Phio Pharmaceuticals Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
773737.61x
Phio Pharmaceuticals Corp's market cap is 773737.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $493.19 Billion | $19.00K | -$8.99 Million | 25957301.16x | N/A |
| 2017 | $383.54 Billion | $15.00K | -$12.45 Million | 25569172.50x | N/A |
| 2018 | $22.77 Billion | $138.00K | -$7.36 Million | 164965.30x | N/A |
| 2019 | $11.80 Billion | $21.00K | -$8.84 Million | 561909.45x | N/A |
| 2020 | $3.38 Billion | $4.36K | -$8.79 Million | 773737.61x | N/A |
Competitor Companies of PHIO by Market Capitalization
Companies near Phio Pharmaceuticals Corp in the global market cap rankings as of June 18, 2026.
Key companies related to Phio Pharmaceuticals Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Phio Pharmaceuticals Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Phio Pharmaceuticals Corp's market cap moved from $2.64 Trillion to $ 12.55 Million, with a yearly change of -68.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.55 Million | +2.86% |
| 2025 | $12.20 Million | -41.67% |
| 2024 | $20.91 Million | -73.68% |
| 2023 | $79.46 Million | -82.97% |
| 2022 | $466.73 Million | -62.80% |
| 2021 | $1.25 Billion | -62.83% |
| 2020 | $3.38 Billion | -71.40% |
| 2019 | $11.80 Billion | -48.17% |
| 2018 | $22.77 Billion | -94.06% |
| 2017 | $383.54 Billion | -22.23% |
| 2016 | $493.19 Billion | -81.29% |
| 2015 | $2.64 Trillion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Phio Pharmaceuticals Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.55 Million USD |
| MoneyControl | $12.55 Million USD |
| MarketWatch | $12.55 Million USD |
| marketcap.company | $12.55 Million USD |
| Reuters | $12.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more